Valued at USD 14.21 billion in 2024, the oncology clinical trials market is projected to reach USD 14.93 billion in 2025 and USD 23.50 billion by 2034, growing at a CAGR of 5.17% during the forecast period 2025–2034. Clinical trials assess new treatments, including targeted therapies, immunotherapies, and combination therapies, for safety and efficacy before approval. Growth is driven by rising global cancer cases and increased investment in oncology drug development, and North America was the largest regional market in 2024. Key players include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Ltd.
Rising Cancer Incidence Fuels the Oncology Clinical Trials Market
According to a 2024 World Health Organization report, cancer cases are expected to rise from 20 million in 2022 to more than 35 million by 2050, and cancer caused 9.7 million deaths in 2022. This growing burden underpins demand for the new treatments being evaluated in clinical trials. According to the report, rising global cancer cases and increased investment in oncology drug development are the primary growth drivers, and the market is segmented by cancer type, phase, study design, and region.
Drugmakers are also funding targeted therapies, immunotherapies, and precision medicine. According to the report, this capital supports faster trial starts, more advanced designs, and partnerships with research institutions and contract research organizations. Opportunities lie in the growth of targeted therapies, immunotherapies, and personalized medicine, while high price points and complex regulatory requirements limit adoption.
Browse Insights:
https://www.polarismarketresearch.com/industry-analysis/oncology-clinical-trials-market
Trial Design Innovation and Phase Insights
Sponsors are emphasizing novel trial designs, biomarker-based patient selection, and adaptive protocols to speed approval. The report covers Phase I, II, III, and IV studies. Phase I led in 2024 owing to demand for initial dose and safety testing of novel treatments. Phase II is expected to grow at the highest CAGR, driven by demand for efficacy evaluation and adaptive designs that shorten development timelines.
Market leaders are partnering with contract research organizations, hospitals, and academic institutions to improve trial efficiency, patient access, and global reach. Their strategies combine adaptive designs, biomarker-based enrollment, and a focus on new therapies and combination trials, making design flexibility and patient matching central to competitive positioning. Sponsors that pair biomarker-based patient selection with strong site networks are better placed to meet these expectations.
Industry Developments Shaping Oncology Clinical Trials
In May 2025, Johnson & Johnson presented over 70 studies at ASCO and EHA 2025, covering multiple myeloma, lung, prostate, and colorectal cancers. In September 2025, Olema Oncology partnered with Pfizer on a Phase 1b/2 trial of palazestrant and atirmociclib in ER+/HER2- metastatic breast cancer.
In October 2025, Merck presented more than 100 abstracts at ESMO 2025, covering KEYTRUDA in bladder, ovarian, and lung cancers and R-DXd in platinum-resistant ovarian cancer. Also in October 2025, Theriva Biologics planned to present updated VIRAGE Phase 2b and SYN-004 data at ESMO 2025 and IDWeek 2025, covering pancreatic cancer and transplant patient safety. These programs span early-phase and later-stage studies, from Phase 1b/2 to Phase 2b. Together, these announcements show sponsors advancing programs across multiple myeloma, prostate, colorectal, breast, bladder, ovarian, and pancreatic cancers.
Competitive Landscape in Oncology Clinical Trials
Companies focus on new therapies and combination trials, using partnerships with hospitals and research organizations to improve efficiency and global reach. Oncology Clinical Trials The report's Porter's Five Forces analysis rates rivalry among existing firms as high, supplier and buyer power as moderate, the threat of substitutes as moderate, and the threat of new entrants as low. High price points and complex regulatory requirements remain the key restraints identified for the market. The report's table of contents also lists PESTEL analysis and value chain analysis among its coverage areas.
More Trending Latest Reports By Polaris Market Research:
customer-success-management-market
non-invasive-cancer-diagnostics-market
military-simulation-and-virtual-training-market
viral-vector-and-plasmid-dna-manufacturing-market